ArticleChinese medicine2026
Atractylodis Macrocephalae Rhizoma ameliorates diarrhea induced by cold drinks and a high-fat diet by remodeling gut microecology and restoring barrier function.
Article in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Shenling Baizhu Powder Modulates Gut Microbiota and Bile Acid Signaling to Alleviate Diet-Induced Diarrhea.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundAtractylodis Macrocephalae Rhizoma (AMR) has traditionally been utilized for treating spleen deficiency diarrhea. Nevertheless, the effects and mechanisms of AMR on diarrhea caused by the consumption of cold drinks and a high-fat diet (CDHFD) remain insufficiently understood.
aimThis study aimed to explore the therapeutic effects and mechanisms of AMR in treating CDHFD-induced diarrhea.
methodsAMR was prepared as an aqueous extract, and its chemical composition was analyzed using UPLC-ESI-MS. A diarrhea model was established in ICR mice by exposure to CDHFD for four weeks, with AMR (low/high doses) administered concurrently via oral gavage. Bowel movements were evaluated using indicators such as fecal water content. Systemic inflammation was assessed by measuring pro-inflammatory cytokines via ELISA and performing peripheral blood cell counts. Intestinal barrier integrity was examined via H&E, AB-PAS staining, and immunofluorescence of tight junction proteins. Gut microbiota profiling was performed using 16S rDNA sequencing. Serum lipopolysaccharide (LPS) levels were measured via ELISA to assess translocation. Finally, the regulatory effects of AMR on the A20/TRAF6/NF-κB signaling pathway were validated using Western blotting. Spearman's correlation analysis was employed to integrate microbiota changes with host inflammatory phenotypes.
resultsAMR significantly ameliorated CDHFD-induced diarrhea. Mechanistically, AMR remodeled the gut microecology by enriching beneficial bacteria, particularly Lachnospiraceae_NK4A136 and norank_f_Muribaculaceae. Concurrently, it increased the number of goblet cells and regulated the expression of tight junction proteins to repair intestinal barrier damage and reverse hyperpermeability. The restoration of barrier function effectively blocked the systemic translocation of LPS, which subsequently inhibited the hyperactivation of the NF-κB signaling pathway, thereby reducing systemic inflammation and ultimately alleviating diarrhea.
conclusionAMR exerts protective effects against CDHFD-induced diarrhea through microbiota-driven intestinal barrier restoration, which sequentially blocks the activation of the LPS/NF-κB inflammatory pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.